Wockhardt Ltd (WOCKPHARMA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Wockhardt Ltd on NSE and BSE, with an AI summary of each filing.
Please refer the attachment.
Others (Uncategorized) · 02 Nov 2026, 11:09 pm
Wockhardt QIP Proceeds Utilization Report for Quarter Ended 30th Sep'26 CRISIL Ratings issued the Monitoring Agency Report for Wockhardt Limited's Rs 1,000.00 crore QIP for the quarter ended 30th Sep'26, confirming zero object deviations. Of the revised net proceeds of Rs 977.79 crore, the company has utilized Rs 893.32 crore cumulatively, including Rs 54.23 crore deployed during the quarter toward capex and R&D. Debt prepayment of Rs 500.00 crore and general corporate purposes of Rs 227.79 crore are fully completed. Unutilized funds of Rs 84.47 crore remain parked primarily in mutual funds, with capex completion extended to FY28.
Appointment of Mr. Sumit Garg as Chief Digital & Information Officer as Senior Management Personnel of the Company.
Change in Management · 02 Nov 2026, 10:39 pm
Wockhardt Designates Sumit Garg as Senior Management Personnel Wockhardt Limited’s Board of Directors has designated Chief Digital & Information Officer (CDIO) Mr. Sumit Garg as Senior Management Personnel, effective 2nd Nov'26, under full-time employment. Garg brings over 30 years of technology and digital transformation experience across pharmaceuticals, life sciences, FMCG, and automotive sectors. He previously served as Vice President and Global CIO at Piramal Pharma Solutions and spent over two decades at GSK Consumer & Pharma in leadership roles, including Director IT for the APAC region.
Please refer the attachment.
Press Release · 02 Nov 2026, 10:30 pm
Wockhardt Reports Q2 FY27 Financial Results and Novel Antibiotic Portfolio Progress Wockhardt reported Q2 FY27 revenue of Rs 969 Cr, up 24% YoY, while EBITDA rose 3% YoY to Rs 165 Cr (Rs 201 Cr excluding pre-Zaynich launch expenses). PAT stood at Rs 73 Cr versus Rs 82 Cr in Q2 FY26. Biotech operations surged 68% YoY to Rs 252 Cr, driven by Emerging Markets growth of 52% YoY to Rs 310 Cr. Key pipeline milestones include US FDA approval for Zaynich, EMA review progression, and the completion of Phase 2/3 trials for Foviscu.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of directors at its meeting held today, i.e. 2nd November, 2026, inter-alia, ....
Financial Result · 02 Nov 2026, 10:12 pm
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/042 dated 27th October, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 2nd November, 2026, inter-alia, has approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter and half year
Outcome · 02 Nov 2026, 9:52 pm
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company, at its meeting ....
Outcome · 02 Nov 2026, 9:51 pm
Wockhardt Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 969 (+23.9% YoY | +4.3% QoQ) ■ EBITDA: 173 (-2.8% YoY | -9.9% QoQ) ■ EBITDA Margin (%): 17.9 (-491 bps YoY | -281 bps QoQ) ■ PAT: 79.0 (+1.3% YoY | -25.5% QoQ) ■ EPS (INR): 4.85 (+0.8% YoY | -26.0% QoQ)
We wish to inform that Share Allotment Committee of Board of Directors of the Company has allotted 20000 equity shares of face value of Rs 5 each on 27th October, 2026 pursuant to exercise ....
Others (Uncategorized) · 27 Oct 2026, 6:03 pm
Wockhardt Allots Equity Shares Under Employee Stock Option Scheme Wockhardt Limited's Share Allotment Committee approved the allotment of 20,000 equity shares of face value Rs. 5 each on 27th Oct'26 under the Employee Stock Options Scheme - 2011. Following this allotment, the company's paid-up equity share capital increased from Rs. 81,24,60,845 (comprising 16,24,92,169 shares) to Rs. 81,25,60,845 (comprising 16,25,12,169 shares). The newly issued shares rank pari-passu with existing equity shares and are eligible for all subsequent corporate benefits and dividends.
WOCKHARDT LIMITED has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 02 Nov 2026, 5:30 am
Wockhardt Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI ....
Intimation · 02 Nov 2026, 5:30 am
Wockhardt Board Meeting Scheduled for 2nd Nov'26 to Consider Q2 Results Wockhardt Limited's Board of Directors is scheduled to meet on 2nd Nov'26 to consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ended 30th Sep'26. In accordance with insider trading regulations, the trading window for dealing in company shares has been closed since 1st Oct'26 and will remain shut until 48 hours following the declaration of the financial results.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 02 Nov 2026, 5:30 am
Pursuant to Regulation 30 (read with Part A of Schedule III) of SEBI (LODR) Regulations 2015, we wish to inform you that the Company is in receipt of an Adjudication Order passed by Commissioner ....
Others (Uncategorized) · 26 Aug 2026, 12:20 am
Wockhardt Receives Customs Order with Penalties Totaling ₹15 Crore Wockhardt received an adjudication order on 21st Aug'26 from the Commissioner of Customs, Nhava Sheva-II. The order imposes a penalty of ₹5 Cr and a redemption fine of ₹10 Cr related to the alleged mis-classification of an exported Active Pharmaceutical Ingredient (API). A separate ₹1 Cr penalty was levied on a company officer. Wockhardt states the order has no material impact on financials or operations beyond the monetary fine. The company is confident in its case and intends to appeal the decision.
Please find enclosed herewith Scrutinizer''s Report on the combined voting results of remote e-voting and e-voting during the 27th AGM of the Company
Annual General Meeting · 11 Aug 2026, 1:15 am
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (LODR) Regulations, 2015, the Proceedings of the 27th AGM of the Company
Annual General Meeting · 11 Aug 2026, 1:08 am
Pursuant to Regulation 32(6) of SEBI (LODR) Regulations 2015, read with Regulation 173A of SEBI (ICDR) Regulations, 2018, please find enclosed Monitoring Agency Report towards utilisation ....
Others (Uncategorized) · 11 Aug 2026, 12:08 am
Wockhardt: QIP Proceeds Utilization Report for Quarter Ended Jun 30, 2026 Wockhardt confirmed no deviation in using its QIP proceeds for the quarter ended Jun 30, '26. The Nov '24 QIP raised net proceeds of ₹977.79 Cr. As of quarter-end, ₹839.09 Cr was utilized, leaving an unutilized balance of ₹138.70 Cr, primarily for capex and R&D. The timeline for capex utilization has been extended to FY28. Proceeds of ₹500 Cr for debt repayment and ₹227.79 Cr for corporate purposes were fully utilized by Mar 31, '26. Unutilized funds are invested in mutual funds.
Please find enclosed Press Release - "Wockhardt Antibiotic Academy, an initiative for Patient-Centric Scientific Dialogue to Tackle Multidrug Resistance".
Press Release · 10 Aug 2026, 11:35 pm
Wockhardt Launches Antibiotic Academy to Combat Multidrug Resistance Wockhardt launched its Antibiotic Academy on 10th Aug'26, an initiative to tackle antimicrobial resistance (AMR) in India. The platform aims to provide continuous medical education for healthcare professionals through scientific dialogue and clinical experience sharing. This initiative leverages the company's focus on anti-bacterial drugs, where it holds USFDA QIDP status for six programmes. Wockhardt highlights that AMR causes ~10 lakh deaths annually in India, underscoring the need for evidence-based solutions and better-informed clinical decisions.
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026
Press Release · 10 Aug 2026, 10:18 pm
Wockhardt Q1 FY27 Results: PAT Reaches Rs. 107 Cr with Strong Revenue Growth Wockhardt reported robust Q1 FY27 results with a PAT of Rs. 107 Cr, a significant turnaround from a loss of Rs. 108 Cr in Q1 FY26. Total revenue grew 26% YoY to Rs. 929 Cr, driven by strong performance in key segments. EBITDA surged 86% YoY to Rs. 188 Cr, with margins expanding to 20.2% from 13.7%. The biotech business was a key driver, growing 112% YoY to Rs. 236 Cr, fueled by a 146% rise in the Emerging Market biotech segment.
Pursuant to Regulation 30 of SEBI Listing Regulations, the Board of Directors at its meeting held today i.e. 10th August, 2026, has approved the Unaudited Financial Results (Standalone ....
Financial Result · 10 Aug 2026, 9:00 pm
Wockhardt Q1 FY27 Results: Consolidated PAT Reverses to Profit Wockhardt reported a turnaround for the quarter ended 30 Jun'26, posting a consolidated PAT of ₹107 Cr against a loss of ₹108 Cr YoY. Revenue from operations grew 25.9% YoY to ₹929 Cr. On a QoQ basis, revenue declined 3.7% while PAT fell 34.8% from ₹164 Cr. Standalone PAT stood at ₹107 Cr, up 55.1% YoY from ₹69 Cr, with revenue from operations at ₹561 Cr, a 35.8% YoY increase. The board approved these unaudited results on 10 Aug'26.
Pursuant to Regulation 30 of SEBI Listing Regulations, Board of Directors at its meeting held today i.e 10th August, 2026 has approved the Unaudited Financial Results (Standalone and Consolidated) ....
Outcome · 10 Aug 2026, 8:54 pm
Wockhardt Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Crore) ■ Revenue: 929 (+25.9% YoY | -3.7% QoQ) ■ EBITDA: 192 (+166.7% YoY | -14.7% QoQ) ■ EBITDA Margin (%): 20.7 (+1091 bps YoY | -265 bps QoQ) ■ PAT: 106 (Loss to Profit YoY | -36.1% QoQ) ■ EPS (INR): 6.55 (Loss to Profit YoY | -35.9% QoQ)
Please find enclosed herewith the addendum to the Notice of the 27th Annual General Meeting of the Company scheduled to be held on Monday, 10th August, 2026.
Annual General Meeting · 06 Aug 2026, 2:16 am
Wockhardt Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI ....
Intimation · 10 Aug 2026, 5:30 am
Wockhardt Board Meeting on 10-Aug-26 to Approve Q1FY27 Financial Results Wockhardt's Board of Directors will meet on Monday, 10-Aug-26, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30-Jun-26. In connection with this, the trading window for dealing in the company's shares, closed since 01-Jul-26, will remain shut until 48 hours after the results are declared on 10-Aug-26.
Please find enclosed the Business Responsibility and Sustainability Report and Independent Assurance Statement on BRSR Core parameters issued by SGS India Private Limited for the Financial ....
Others (Uncategorized) · 18 Jul 2026, 2:16 am
Wockhardt Submits FY26 Business Responsibility and Sustainability Report Wockhardt filed its Business Responsibility and Sustainability Report for the year ended 31st Mar'26. Exports contributed 56.86% to total turnover, with manufacturing activities accounting for 81%. For FY26, total Scope 1 GHG emissions were 10,430.89 tCO2e, and Scope 2 emissions were 49,637.06 tCO2e. The company reported a total turnover of ₹17,38,69,94,357 and a net worth of ₹26,42,57,59,143. Gross wages paid to females increased to 13.91% of total wages, up from 8.93% in FY25. The report includes an independent assurance statement from SGS India.
Please find enclosed herewith the Annual Report of the Company for the Financial Year 2025-26.
Others (Uncategorized) · 18 Jul 2026, 2:03 am
Please find enclosed herewith the Notice of 27th Annual General Meeting of Wockhardt Limited scheduled to be held on Monday, 10th August, 2026, at 3:30 p.m. through Video Conferencing/ ....
Annual General Meeting · 18 Jul 2026, 1:52 am
Pursuant to Regulation 30 of the Securities and Exchange Board of India (LODR) Regulations, 2015, as amended and in continuation to our letter bearing reference no. Ref.no. WOCK/SEC/SE/2025-26/015 ....
Transcript · 11 Jun 2026, 6:24 pm
Pursuant to Regulation 30 of SEBI (LODR), Regulations, 2015, please find enclosed herewith copy of the Investor Presentation to be made at the Investor Meeting scheduled to be held on 4th June, 2026.
Investor Presentation · 04 Jun 2026, 9:54 pm
Wockhardt FY26 Turnaround Driven by Profitability Focus and Strategic Shifts Wockhardt reported FY26 income of INR 3,373 Cr. and EBITDA of INR 630 Cr., a 51% YoY growth. Profitability improved significantly with EBITDA margin expanding to 18.6% from 5.4%, driven by exiting the US generics business and focusing on high-margin products. The balance sheet strengthened with cash at INR 662 Cr. and Net Debt/Equity at 0.10. Growth was led by Emerging Markets (+35% YoY) and the UK (+13% YoY). Future strategy centers on the global launch of its novel antibiotic, Zaynich, and expanding its biosimilar diabetes franchise.